Farms.com Home   Ag Industry News

CMC says European beef and pork producers will have benefit over Canadian farmers under CETA

CMC says European beef and pork producers will have benefit over Canadian farmers under CETA

Some Canadian treatments haven’t been approved by the European Union

By Diego Flammini
News Reporter
Farms.com

The Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union (EU) will benefit European beef and pork farmers, according to the Canadian Meat Council (CMC).

CETA contains two provisions that give European farmers an advantage over their Canadian counterparts, according to the CMC.

The first provision revolves around the placement of an EU health mark.

“There is a provision in the current (Canadian Food Inspection Agency) regulations which require that the EU health mark be applied at the production plant,” Ron Davidson, director of international trade, government and media relations with CMC, told Farmscape today.

Placing the health mark at the production plant is an issue, Davidson says, because exporting pork to the EU requires a cold treatment. CMC would like the health marks to be placed on boxes of meat after the cold storage treatments.

And the second provision pertains to a Canadian antimicrobial treatment.

The current antimicrobial measures used by Canadian processors isn’t currently approved by the EU. And until an agreement can be reached, Canadian meat producers may be at a disadvantage.

“The industry expectation is that, once the supplemental research has been completed, these antimicrobial interventions will receive timely approval by the EU regulatory authorities,” says a Sept. 21 CMC release.

Under CETA, which came into effect on Sept. 21, Canadian producers will duty-free export 80,549 tonnes of pork, 64,950 tonnes of beef and veal, 3,000 tonnes of bison and unlimited exports of horsemeat.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.